Details

Autor(en) / Beteiligte

• Dimopoulos, Meletios A
• Oriol, Albert
• Nahi, Hareth
• San-Miguel, Jesus
• Bahlis, Nizar J
• Usmani, Saad Z
• Rabin, Neil
• Orlowski, Robert Z
• Komarnicki, Mieczyslaw
• Suzuki, Kenshi
• Plesner, Torben
• Yoon, Sung-Soo
• Ben Yehuda, Dina
• Richardson, Paul G
• Goldschmidt, Hartmut
• Reece, Donna
• Lisby, Steen
• Khokhar, Nushmia Z
• O’Rourke, Lisa
• Chiu, Christopher
• Qin, Xiang
• Guckert, Mary
• Ahmadi, Tahamtan
• Moreau, Philippe

Titel

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Ist Teil von

• The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Electronic Journals Library - Freely accessible e-journals

Beschreibungen/Notizen

• The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide and dexamethasone alone, at a cost of more frequent neutropenia and infusion reactions. The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved outcomes in patients with multiple myeloma over the past 10 years, 1 – 3 but most patients still eventually have a relapse. 4 Relapse can occur even after standard complete remission in the context of first-line therapy, and studies are therefore evaluating deeper responses in a category termed “minimal residual disease–negative” (i.e., results below the threshold for minimal residual disease) that is prognostic with regard to a rate of disease progression in a time-to-event analysis and overall survival. 5 , 6 However, this category of minimal residual disease status has . . .